"While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," said Dr Tedros ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...

South Asia has achieved its highest-ever immunization coverage for children, with notable progress in India and Nepal, ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Kenya is among nine African countries selected to introduce Lenacapavir, a groundbreaking long-acting injectable HIV ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...